Norwegian version of this page


Multiple sclerosis (MS) is an autoimmune disease that impacts the central nervous system. Worldwide, over 2 million patients are affected by the disease, which is one of the most common causes of disability amongst the younger inhabitants of Europe.

About the project

Multiple manifestations of genetic and non-genetic factors in Multiple Sclerosis disentangled with a multi-omics approach to accelerate personalised medicine. – MultipleMS

MultipleMS has 22 partners originating from 15 countries, with the main hub at the Karolinska Institutet, Stockholm, Sweden. The consortium will grow by addition of new centres of excellence during the project phase.


The main objective of MultipleMS is to develop novel personalised medicine approaches for multiple sclerosis (MS) patients. Our goal is timely, not only because there is an urgent need for precision management of MS but also because necessary knowledge, methodologies and vast multi-layer data resources are now available.


MultipleMS will identify stratified patient populations utilizing unprecedented large cohorts rich in genetic, lifestyle, clinical, imaging and DMT response data. Such datasets exist in several research groups worldwide, MultipleMS joins these individual datasets into a single analysis database which gives a considerable increase in the power to detect strata. In addition, publically available large scale ‘multi- omics’ data, in particular high-resolution maps of immune cells, in combination with ‘multi-omics’ data from MS patients, will empower identification of biological pathways underlying stratified patient populations. MultipleMS will further validate these pathways in a prospective observational study, prioritize novel therapeutic targets and initiate a drug development program.

More about MultipleMS

Published Dec. 21, 2020 3:21 PM - Last modified Dec. 21, 2020 3:21 PM


Prosject leader

Contact person